Effect of Prostatan on symptoms of patients with benign prostatic hyperplasia
Phase 3
Recruiting
- Conditions
- Benign prostatic hyperplasia.Benign neoplasm of prostateD29.1
- Registration Number
- IRCT20150420021869N6
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 80
Inclusion Criteria
Diagnosed with benign prostatic hyperplasia based on clinical diagnosis
Moderate lower urinary tract symptoms due to IPSS score
Age more than 40 years old
Exclusion Criteria
Not having consent to enter the study
Patients having lower urinary tract symptoms due to other causes including ureteral stricture, prostate cancer, bladder neck cancer, bladder or ureteral stone, neurogenic bladder, or urinary tract infection
Patients with liver or kidney failure
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method IPSS score. Timepoint: At baseline and 3 months after intervention. Method of measurement: IPSS questionnaire.
- Secondary Outcome Measures
Name Time Method Serum PSA level. Timepoint: At baseline and 3 months after intervention. Method of measurement: Blood sampling.